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Abstract Lectin-like oxidized low-density lipoprotein receptor-
1 (LOX-1) is a member of the scavenger receptor family, and is
known to be expressed in monocytes/macrophages. We investi-
gated the effect of histamine on the expression of LOX-1 in cells
of the human monocytic leukemia cell line THP-1. Histamine as
well as forskolin and dibutyryl cyclic AMP (Bt2-cAMP)
stimulated the THP-1 monocytes to express the LOX-1 gene
at the transcription level. This histamine effect on LOX-1 gene
expression, via the histamine H2 receptor-mediated cAMP signal
transduction pathway, was reduced after differentiation of the
cells into macrophages, even though forskolin and Bt2-cAMP
still enhanced the gene expression. The alteration of the
responsiveness of LOX-1 expression to histamine was related
to suppressed expression of the H2 receptor in THP-1
macrophages. The switch of the predominant class of histamine
receptors between H1 and H2 would modulate the effects of
histamine on LOX-1 gene expression in monocytes and
macrophages, and therefore, would play a certain role in the
inflammatory aspects of atherogenesis. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Histamine is synthesized from L-histidine by histidine decar-
boxylase (HDC) in a single enzymatic step, and it is one of the
principal mediators related to allergic reactions, in£ammation
[1^3], neurotransmission [4] and cardiovascular hemodynam-
ics [5]. Many types of cells express speci¢c histamine recep-
tors, which are classi¢ed into H1, H2, and H3 types [6^8]. The
H1 receptor couples to Gq and the phosphoinositol hydrolysis
pathway, while the H2 receptor links to Gs to activate ade-
nylate cyclase. Recently, a gene for the histamine H3 receptor,
the product of which couples to Gi, has been cloned [9], and
the presence of another type of histamine receptor, H4 recep-
tor, has also been reported [10,11]. We previously reported
that histamine H1 receptor is predominantly expressed in vas-
cular smooth muscle and endothelial cells [11] and that hista-
mine stimulates vascular smooth muscle cells to proliferate via
the H1 receptor [12]. Furthermore, our recent work demon-
strated that a switch of histamine receptor from H2 to H1
takes place during macrophage di¡erentiation and that this
receptor switch is closely related to regulation of lipopolysac-
charide-induced expression of tumor necrosis factor-K (TNF-
K) by histamine [13]. Knowledge about the diversity of hista-
mine receptors expressed on the cells constituting the athero-
sclerotic vascular wall would be very important for a better
understanding of the physiological and pathological roles of
histamine.
Monocytes/macrophages play a central role in atherogene-
sis, and they exhibit multiple functions in relation to the for-
mation of the atherosclerotic lesion, which include monocytic
migration and secretion of growth factors, cytokines, and ma-
trix-degrading enzymes [14]. On the other hand, scavenger
receptors are key molecules that allow monocytes/macro-
phages to take up modi¢ed lipoproteins and to become trans-
formed into foam cells [15]. Many types of scavenger recep-
tors are reported to exist on the monocyte/macrophage [15],
and the lectin-like oxidized low-density lipoprotein receptor-1
(LOX-1) is the major receptor for oxidized low-density lipo-
protein (LDL) [16,17]. In£ammatory and immunologic events
are involved in the pathogenesis of atherosclerosis, and
oxidized LDL is one of the activators of T-lymphocytes
and macrophages in the vascular wall [18^20]. In fact, expres-
sion of LOX-1 has been reported in endothelial cells, macro-
phages, and smooth muscle cells in the intima of the athero-
sclerotic lesion [21]. We recently demonstrated that activated
monocytes and T-lymphocytes expressed HDC mRNA in
vitro and in atheromatous plaques as a non-mast cell source
of histamine [22]. Therefore, it is necessary to examine the
e¡ects of histamine on LOX-1 gene expression to understand
the mechanism of initiation and progression of atherosclero-
sis.
In the present study, we demonstrated that LOX-1 gene
expression is regulated through the cyclic AMP signaling
pathway and that histamine up-regulates the LOX-1 expres-
sion via the H2 receptor in THP-1 monocytes.
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2. Materials and methods
2.1. Chemicals
Forskolin, protein kinase A (PKA) inhibitor (H89), nitroblue tetra-
zolium (NBT), and tetradecanoylphorbol-13-acetate (TPA) were ob-
tained from Sigma (St. Louis, MO, USA). Histamine was from Wako
Pure Chemical Industries (Tokyo, Japan). Dibutyryl cyclic AMP (Bt2-
cAMP) was from Biomol Research Laboratories (Plymouth Meeting,
PA, USA); and the histamine H2 receptor agonist dimaprit dihydro-
chloride was from Tocris Cookson Ltd. (Ballwin, MO, USA). Pros-
taglandin E2 and D2 (PGE2 and PGD2) were obtained from Cayman
Chemical (Ann Arbor, MI, USA). Anti-human CD68 mouse mono-
clonal antibody for £ow cytometric analyses was purchased from BD
PharMingen (San Diego, CA, USA).
2.2. Cell culture
The human monocytic leukemic cell line THP-1 was obtained from
American Type Culture Collection (TIB-202) and maintained in
RPMI 1640 medium (Sigma) containing 5% fetal calf serum (FCS,
ICN, Costa Mesa, CA, USA) at 37‡C in an atmosphere of 95% air
and 5% CO2.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNAs extracted from the THP-1 cells were subjected to re-
verse transcriptase reaction and PCR, and the primers for ampli¢ca-
tion of histamine H1 and H2 receptor cDNAs were designed and used
for PCR as previously reported [13]. For PCR ampli¢cation of hista-
mine H3 (GenBank accession number AL078633) and H4 (GenBank
accession number NM021624) receptor cDNAs, two sets of primers,
5P-TCCTCTGCCTTCAACATCG-3P/5P-ATCATCAGCAGCGTGT-
ATGG-3P (to generate a 779-bp fragment) and 5P-GAATTGTCT-
GGCTGGATTTTAAAGCTAATTTG-3P/5P-AAGAATGATGTGA-
TGGCAAGGATGTACC-3P (to generate a 596-bp fragment), were
used, respectively. Denaturation, annealing and extension tempera-
tures were 35 cycles of 94‡C for 1 min, 58‡C for 1 min, and 72‡C
for 1.5 min, for H3 receptor, and 2 times repeated PCRs of each 20
cycles at the same temperature condition of H3, for H4 receptor. All
the ampli¢ed fragments were cloned into pGEM-T Easy vector
(Promega, Madison, WI, USA) and sequenced.
2.4. Northern blotting
The THP-1 cells were stimulated with TPA (20 ng/ml) for 24 h in
RPMI 1640 containing 5% FCS and further incubated in RPMI 1640
containing 0.5% FCS for 48 h for di¡erentiation into macrophages.
Then the THP-1 macrophages were stimulated with histamine (50
WM), forskolin (10 WM) or Bt2-cAMP (200 WM) for the desired peri-
ods. Monocytic THP-1 cells were also used for the same experiment.
Total RNAs were extracted by Trizol reagent (Gibco BRL, Rockville,
MD, USA) and electrophoresed on 1% agarose gel containing 6%
formaldehyde (20 Wg/lane). After the RNAs had been transferred
onto a nylon membrane, expression of LOX-1 mRNAs was detected
by hybridization with 32P-labeled LOX-1 probe. The LOX-1 cDNA
probe was generated by RT-PCR from the THP-1 cell mRNA by
using primers to amplify a full-length 848-bp fragment according to
the reported cDNA sequence (GenBank accession number
HSA131757). The membrane was exposed to X-ray ¢lm at 380‡C
overnight or longer. Equal loading of the RNAs for each sample
was con¢rmed by methylene blue (0.02% in 0.5 M sodium acetate,
pH 5.2) staining of the membrane to visualize 28S and 18S ribosomal
RNAs (data not shown). The ampli¢ed histamine receptor cDNA
fragments (H1, H2 and H4) were also used for probes of Northern
blotting after 32P labeling.
2.5. Cloning of LOX-1 promoter
Based on the reported sequence data (GenBank accession number
AB021922) of the human LOX-1 promoter region [23], a 1053-bp
fragment corresponding to nucleotides 31017 to +36 was generated
by PCR from genomic DNA of the THP-1 cells as a template. After
the sequence had been con¢rmed, the fragment was ligated to a lu-
ciferase reporter vector, pGL3-basic (Promega) at MluI and HindIII
sites (pLOX-Luc). A pLOX-CREm-Luc construct was generated by a
substitution of GT to CA (3112 and 3111) by site-directed muta-
genesis to introduce a mutation in the cyclic AMP response element
(CRE).
2.6. Transfection and luciferase assay
The monocytic THP-1 cells (1.4U107/0.5 ml/cuvette) were trans-
fected with 20 Wg of reporter constructs along with 0.5 Wg of L-gal
expression vector by electroporation at a setting of 950 WF and 300
kV (GenePulsar II, Bio-Rad, Hercules, CA, USA). The cells were
lysed and mixed with luciferase substrate (Toyo Ink, Tokyo, Japan)
for measurement of luciferase activity 8 h after the electroporation. To
decrease variation in transfection e⁄ciency, we transfected the cells in
a single batch for each reporter plasmid, which was then separated to
the desired numbers of wells. Further, L-gal activity was measured to
monitor the transfection e⁄ciency. For co-transfection studies, pMT-
Pka (gift from Dr. Marc Montminy [24]) and pCREB341 (gift from
Dr. Richard H. Goodman [25]) were used for the luciferase reporter
assays at a dose of 1.0 and 2.0 Wg per electroporation cuvette, respec-
tively.
2.7. Analyses for macrophage di¡erentiation
To investigate macrophage di¡erentiation by histamine, we exam-
ined the expression of CD68 and capacity for NBT reduction. The
monocytic THP-1 cells were incubated with histamine (50 WM) for
3 days and then subjected to £ow cytometry (Epics XL, Beckman
Coulter, Miami, FL, USA) and NBT reduction assay. As a positive
control for macrophage di¡erentiation, the THP-1 cells were stimu-
lated with Bt2-cAMP (200 WM) for the same period.
3. Results and discussion
Many genes are expressed in accordance with macrophage
di¡erentiation [26], and LOX-1 expression has been reported
to increase during TPA-induced macrophage di¡erentiation of
THP-1 cells [27]. Our results con¢rmed that the THP-1 cells
after di¡erentiation into macrophages expressed LOX-1
mRNA (Fig. 1A, row 3) and showed that the basal expression
in the monocytic condition was very low (Fig. 1A, row 1).
However, longer exposure of the Northern blot membrane
revealed that the monocytic THP-1 cells also expressed
LOX-1 mRNA and that the expression was induced by hista-
mine (Fig. 1A, row 2). No mRNA induction by histamine
over the control level was detected in the THP-1 macrophages
(Fig. 1A, row 3). In contrast, cAMP-elevating agents, forsko-
lin and Bt2-cAMP, apparently enhanced the expression of
LOX-1 mRNA in both monocytic and macrophage THP-1
cells. This histamine-induced LOX-1 mRNA expression in
monocytic THP-1 cells was observed as early as 2 h after
the start of stimulation (Fig. 1B). These results indicate that
Fig. 1. Northern blot analyses of LOX-1 gene expression in THP-1
cells. A: E¡ects of cAMP-elevating agents on LOX-1 mRNA ex-
pression. Row 1 (overnight exposure) and row 2 (longer exposure),
THP-1 monocyte; row 3 (overnight exposure), THP-1 macrophage.
Note the increased mRNA expression by cAMP-elevating agents
(forskolin, 10 WM; Bt2-cAMP, 200 WM) in both monocytes and
macrophages but histamine (50 WM) stimulated monocytes to up-
regulate LOX-1 mRNA expression. All the agents were incubated
with the cells for 2 h. B: Time course study of LOX-1 mRNA ex-
pression by histamine stimulation (50 WM). The maximal induction
was observed with 2 h stimulation.
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LOX-1 expression is up-regulated by cAMP-elevating agents,
including histamine, the H2 receptor of which couples to Gs
to elevate the cytoplasmic concentration of cAMP.
To determine whether the di¡erences in histamine respon-
siveness between the monocytes and macrophages resulted
from expression of di¡erent receptor types, we applied the
mRNAs to RT-PCR to obtain the receptor expression pro¢le.
As shown in Fig. 2A, the monocytic THP-1 cells expressed a
higher amount of H2 receptor than of H1 receptor. In con-
trast, after macrophage di¡erentiation by TPA treatment, the
H1 receptor expression was induced and the H2 receptor ex-
pression was reduced. Histamine H3 receptor mRNAs were
not detected in either condition, whereas H4 receptor expres-
sion was very faintly detected in macrophages (arrowhead,
Fig. 2A). To con¢rm the receptor expression pro¢le in the
THP-1 cells, we performed Northern blot analysis using H1,
H2, and H4 receptor cDNA probes. The switch of the pre-
dominant histamine receptor type from H2 to H1 during mac-
rophage di¡erentiation was clearly demonstrated by this anal-
ysis (Fig. 2B). H4 receptor expression was not detected in our
experimental conditions (data not shown). Fig. 3A shows the
quantitative analysis of the receptor expression pro¢le in re-
sponse to di¡erentiation. The histamine receptor pro¢le was
H2 dominant in the monocytic condition, while it was H1
dominant in the macrophage condition (Fig. 3A). This pattern
is exactly the same as that observed in another human mono-
cytic cell line, U937, in which histamine receptor switching
from H2 to H1 was demonstrated during macrophage di¡er-
entiation [13]. The responsiveness of LOX-1 mRNA expres-
sion to histamine was higher in the monocytic condition (Fig.
3B). The signal transduction pathway triggered by elevated
cAMP would be well preserved in either condition of the
THP-1 cells, since forskolin and Bt2-cAMP up-regulated
LOX-1 mRNA expression in both monocytes and macro-
phages (Fig. 1). Taken together, the results suggest that the
higher response of the monocytic THP-1 cells to histamine is
based on the predominant H2 receptor expression.
To address whether histamine transcriptionally up-regulates
the LOX-1 gene in the monocytic THP-1 cells through the
cAMP signal transduction pathway, we constructed a lucifer-
ase reporter plasmid including the human LOX-1 promoter
region (pLOX-Luc, Fig. 4A). The cloned promoter region,
spanning from 31017 to +36 of the transcription initiation
site, includes some enhancer elements, but a proximal frag-
ment of 180 bp (3150 to +30) has been reported to be su⁄-
cient to regulate basal promoter activity [23]. This 180-bp
fragment contains an inverted CRE at 3116 to 3109, which
overlaps a GC box. As shown in Fig. 4B, all the cAMP-ele-
vating agents including histamine and H2 receptor agonist
increased the transcriptional activity from the pLOX-Luc
(wild type). Histamine H1 and H3 agonists had no e¡ect on
the activity (data not shown). When THP-1 cells were trans-
fected with pLOX-CREm-Luc (CREm) harboring a mutation
in the CRE (GT to CA), the basal activity was reduced to
20% of that of pLOX-Luc and no induction by the cAMP-
elevating agents was observed (Fig. 4B), indicating that the
CRE motif was essential for both basal activity and the re-
sponse to cAMP-elevating agents. It was reported earlier that
LOX-1 mRNA was up-regulated by TNF-K and transforming
growth factor-L1 in mouse macrophages [17,27], but the mo-
lecular mechanism by which the expression of the LOX-1 gene
is regulated yet to be clari¢ed.
Next we investigated the e¡ect of H89, a PKA inhibitor, on
the promoter activity to con¢rm the involvement of the
cAMP-PKA-CRE pathway for LOX-1 gene regulation. The
H89 treatment reduced the histamine- and H2 agonist-induced
promoter activities and basal activity in a dose-dependent
manner (Fig. 4C). Along with the CRE mutational analysis,
these results suggest the involvement of PKA and its sub-
strate, CRE binding protein (CREB), for the basal and induc-
ible activity of the LOX-1 gene promoter. To clarify this fur-
ther, we introduced PKA and CREB expression vectors into
the luciferase reporter assays. The MT-I promoter drives the
PKA expression vector, pMT-Pka [24], and the expression is
controlled by the addition of zinc ions to the culture medium.
Fig. 2. RT-PCR and Northern blot analyses of histamine receptor
gene expression in THP-1 cells. H1, H2, H3, and H4 refer to hista-
mine H1, H2, H3, and H4 receptor, respectively. A: In the mono-
cytic condition (TPA3), H2 receptor expression is dominant; in
contrast, H2 expression is reduced in the macrophage condition
(TPA+). No H3 receptor expression was detected, whereas a low
level of H4 receptor mRNA expression was noted (arrowhead). Am-
pli¢ed fragments of H1, H2, and H4 receptor cDNA were 492, 498,
and 596 bp, respectively. M, 100-bp ladder DNA size marker. B:
Northern blot analysis con¢rmed the predominant H2 receptor ex-
pression in the monocytes (TPA3) ; in contrast, the H1 receptor
was predominant in the macrophages (TPA+).
Fig. 3. Quantitative analyses of histamine receptor pro¢le and hista-
mine responsiveness. A: Ratio of H2 and H1 receptor expression
was calculated by densitometric analysis of the Northern blot (Fig.
2B). Again note that the histamine receptor expression pro¢le is
predominantly of the H2 type in the monocytic condition. B: Fold
activation by histamine stimulation over the control level of LOX-1
mRNA expression (Fig. 1) was calculated following densitometry of
the histamine responsiveness. Note that the response of LOX-1
mRNA expression to histamine is higher in monocytic THP-1 cells
than in macrophages (MP).
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The CREB expression vector, pCREB341, is driven by Rous
sarcoma virus promoter [25]. Either PKA or CREB over-ex-
pression up-regulated the LOX-1 gene transcription, and co-
transfection further enhanced the promoter activity (Fig. 5,
Wild type). This PKA and CREB e¡ect was not detected
when the cells were co-transfected with pLOX-CREm-Luc
as a reporter (Fig. 5, CREm).
Here we demonstrated that histamine up-regulated LOX-1
gene expression via the H2 receptor in THP-1 cells in the
monocytic state. Since LOX-1 might be a di¡erentiation-re-
lated gene preferentially expressed in macrophages [17,27] and
a report indicated H2 receptor-mediated cellular di¡erentia-
tion of the myelogenic leukemia cell line HL60 [28], we
studied the possibility that histamine might induce macro-
phage di¡erentiation of THP-1 cells. However, even with a
3-day incubation with 50 WM histamine, the monocytic
THP-1 cells did not di¡erentiate into macrophages when the
cells were monitored by CD68 expression, NBT reduction,
and morphological changes as di¡erentiation markers (data
not shown). Similarly the H2 agonist dimaprit had no e¡ect
on cellular di¡erentiation in U937 monocytic cells [29].
Since both histamine and prostaglandins are secreted from
monocytes/macrophages and are present in the environment
of atherosclerotic lesions [22,30^32], we also investigated the
e¡ect of PGE2 and PGD2 on LOX-1 gene expression. North-
ern blot analysis revealed that PGE2 stimulated the macro-
phages, but not the monocytic THP-1 cells, to enhance LOX-1
mRNA expression (Fig. 6). This contrasts with the response
to histamine found in monocytic THP-1 cells (Fig. 1). These
in£ammatory mediators, histamine and PGE2, would thus
play a role in modulating LOX-1 gene expression in mono-
cytes and macrophages, respectively. Interestingly, both hista-
mine and PGE2 inhibited production of the Th1-inducing cy-
tokine interleukin (IL)-12 from monocytes [33,34] ; and, in
Fig. 4. Luciferase reporter analyses of LOX-1 transcription in THP-1 cells. A: Schematic presentation of cloned LOX-1 gene promoter region.
The transcription initiation site is assigned +1. SSRE, shear-stress response element; TRE, TPA response element; GATA-2, GATA-2 protein
binding element; CRE, cAMP response element; CREm, mutated CRE. B: E¡ects of cAMP-elevating agents on promoter activity. The pro-
moter activity from the pLOX-Luc (Wild type) was markedly enhanced by cAMP-elevating agents. Note the reduced basal activity and lack of
response to the cAMP-elevating agents with pLOX-CREm-Luc (CREm). C: E¡ect of H89 on promoter activity. Both basal and inducible ac-
tivities were dose-dependently inhibited by the treatment of H89 for 8 h (open column, 0 Wmol/l; dashed column, 3.3 Wmol/l; closed column,
10 Wmol/l).
Fig. 5. E¡ects of CREB and PKA expression on LOX-1 gene pro-
moter activity. The THP-1 cells were co-transfected with PKA and
CREB expression vectors for promoter assays. Addition of zinc
chloride (100 WM) to the medium increased transcriptional activities
from the wild type pLOX-Luc vector (Wild type). A further increase
in the activity is observed when both PKA and CREB are intro-
duced. Note the lower transcriptional activities from CRE-mutated
(CREm) reporter even when the cells were co-transfected with PKA
and CREB.
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addition, they inhibited IL-2 and interferon-Q (IFN-Q) (Th1
cytokines) but not IL-4 and IL-5 (Th2 cytokines) production
from T-lymphocytes [35^37]. These ¢ndings indicate that his-
tamine suppresses the Th1 immune response in atherosclerotic
lesions, where the Th1-type response is predominant [38,39].
On the other hand, it was reported that Th2 cytokines (IL-4
and IL-13) stimulated monocytes to oxidize LDL and that, in
contrast, IFN-Q inhibited the oxidation [40]. Taken together
with our results, these ¢ndings suggest that histamine may
promote monocytic oxidation of LDL through Th1 suppres-
sion and enhance uptake of oxidized LDL via increased ex-
pression of LOX-1. This seems contrary to the fact that IFN-Q
inhibited either LDL oxidation [40] or scavenger receptor ex-
pression [41]. However, the net e¡ects of histamine on the
immune response in the atherosclerotic lesion are still contro-
versial, because oxidized LDL itself stimulates monocytes to
produce IL-12 [38]. Our observation suggests a potential con-
tributing role of histamine to LOX-1 expression in relation to
immunology, in£ammation, and atherosclerosis.
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Fig. 6. E¡ect of PGE2 and PGD2 on LOX-1 mRNA expression.
Note the increased expression of LOX-1 mRNA elicited by PGE2
in the macrophage condition (MP) of THP-1. No mRNA induction
was observed upon PGD2 stimulation.
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